ASX · ANP.AX
Antisense Therapeutics Limited
A$0.06-A$0.00 (-4.92%)
Antisense Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 47.27% below the high.
Loading market information…
ASX · RSH.AX · AUD
Stock price, earnings
Quote as of Apr 23, 2025, 06:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Respiri Limited’s quoted price sits in the lower half of its reported 52-week range, 67.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Respiri Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Melbourne, Australia, Respiri Limited operates as an e-health software-as-a-service (SaaS) provider. The company is dedicated to the research, development, and commercialization of medical devices across Australia, and also creates, manufactures, and distributes mobile health applications. Its key offerings include wheezo, an innovative electronic tool specifically designed for identifying wheezing in children, along with the Respiri mobile application and the Respiri health portal. The organization officially became Respiri Limited in December 2015, having previously conducted business as iSonea Limited.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.06-A$0.00 (-4.92%)
Antisense Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 47.27% below the high.
A$0.02A$0.00 (0.0%)
LBT Innovations Limited: Healthcare · Medical - Devices.
A$0.01A$0.00 (0.0%)
Creso Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 83.02% below the high.
A$0.04A$0.00 (0.0%)
CardieX Limited’s quoted price sits in the lower half of its reported 52-week range, 79.43% below the high.
A$0.04-A$0.00 (-6.98%)
Rhinomed Limited’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
A$0.02A$0.00 (0.0%)
Oventus Medical Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
A$0.01A$0.00 (0.0%)
Universal Biosensors, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.25% below the high.
A$0.07A$0.00 (0.0%)
Visioneering Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.6% below the high.
